<DOC>
	<DOCNO>NCT02764411</DOCNO>
	<brief_summary>Capillary Malformations ( CM ) affect significant proportion otherwise healthy child may lead psychological discomfort leave untreated . A significant proportion untreated lesion undergo soft tissue thicken darker discoloration later life due progressive ectasia affect vessel . While laser treatment available , use may limit due need repeat sedation/general anesthetic use , partial response cost . The investigator propose conduct open-label , prospective , cohort study use Onreltea ( Brimonidine ) gel treatment facial capillary malformation child . The study medication apply topically affected area skin daily 12 week . Follow visit occur Week 1,4,8,12 , 16 ass efficacy safety propose treatment . The study second aim explore feasibility conduct multicenter placebo control study .</brief_summary>
	<brief_title>Onreltea ( Brimonidine ) Gel In Pediatric Patients With Capillary Malformations</brief_title>
	<detailed_description>The investigator plan enroll study 20 participant SickKids . It prospective , open label , cohort study . Patients enrol study follow Hospital For Sick Children 16 week . They come study visit 6 time : 1 week , 4,8,12 , 16 week treatment start . During study visit study investigator assess change characteristic CM lesion ( ) capture Chromometer * , Analogue Scale Erythema Assessment tool . Participants parent assess change final study visit ( VAS EA tool ) . Patients provide study medication duration study treatment ( 12 week ) . The result treatment compare baseline data evaluate efficacy safety Onreltea ( Brimonidine ) gel child facial capillary malformation .</detailed_description>
	<mesh_term>Congenital Abnormalities</mesh_term>
	<mesh_term>Port-Wine Stain</mesh_term>
	<mesh_term>Vascular Malformations</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<criteria>diagnosis facial capillary malformation ( portwine stain , PWS ) make dermatologist age : 1217 year age weight &gt; 45 kg lesion surface area &lt; 100 cm2 sign consent assent study participation skin breakdown overlie malformation due dermatological condition ( e.g . eczema , psoriasis ) current treatment laser past 3 month topical treatment use within past 4 week ( e.g . rapamycin , corticosteroid , calcineurin inhibitor , etc ) know chronic renal hepatic disorder know cardiovascular disorder systemic medication potentially interact Brimonidine ( opiate , chlorpromazine , methyphenidate , reserpine , etc ) mixed capillary/ venous lymphatic malformation know allergy one constituent Onreltea pregnancy , sexually active subject childbearing potential ( CBP ) , unwilling use contraception study ( barrier method , oral contraceptive ) .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Capillary malformation</keyword>
	<keyword>Onrealtea</keyword>
	<keyword>port-wine stain</keyword>
	<keyword>treatment</keyword>
	<keyword>topical</keyword>
</DOC>